These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31903932)

  • 21. Bullying biosimilars: cheaper drugs stymied in USA.
    The Lancet Gastroenterology Hepatology
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):371. PubMed ID: 29739669
    [No Abstract]   [Full Text] [Related]  

  • 22. [Antibody alternative formats: antibody fragments and new frameworks].
    Kitten O; Martineau P
    Med Sci (Paris); 2019 Dec; 35(12):1092-1097. PubMed ID: 31903922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutting-edge capillary electrophoresis characterization of monoclonal antibodies and related products.
    Gahoual R; Beck A; Leize-Wagner E; François YN
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():61-78. PubMed ID: 27265157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boehringer splashes out on bispecific antibody platforms.
    Moran N
    Nat Biotechnol; 2011 Jan; 29(1):5-6. PubMed ID: 21221079
    [No Abstract]   [Full Text] [Related]  

  • 25. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development trends for therapeutic antibody fragments.
    Nelson AL; Reichert JM
    Nat Biotechnol; 2009 Apr; 27(4):331-7. PubMed ID: 19352366
    [No Abstract]   [Full Text] [Related]  

  • 28. Production technologies for monoclonal antibodies and their fragments.
    Andersen DC; Reilly DE
    Curr Opin Biotechnol; 2004 Oct; 15(5):456-62. PubMed ID: 15464378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expectations for Phase-Appropriate Drug Substance and Drug Product Specifications for Early-Stage Protein Therapeutics.
    Kretsinger J; Frantz N; Hart SA; Kelley WP; Kitchen B; Novick S; Rellahan B; Stranges D; Stroop CJM; Yin P; Gastens MH
    J Pharm Sci; 2019 Apr; 108(4):1442-1452. PubMed ID: 30528942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First US biosimilar launch.
    Nat Biotechnol; 2015 Oct; 33(10):1013. PubMed ID: 26448071
    [No Abstract]   [Full Text] [Related]  

  • 31. [The long path (s) of placing medicines on the market].
    Duguet C
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():13-17. PubMed ID: 30943154
    [No Abstract]   [Full Text] [Related]  

  • 32. Arming antibodies: prospects and challenges for immunoconjugates.
    Wu AM; Senter PD
    Nat Biotechnol; 2005 Sep; 23(9):1137-46. PubMed ID: 16151407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintaining 'standards' for biosimilar monoclonal antibodies.
    Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
    Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
    [No Abstract]   [Full Text] [Related]  

  • 34. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
    Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
    MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibodies and their multivalent constructs for cancer therapy.
    Li Q; Yi L; Marek P
    Protein Pept Lett; 2014; 21(10):1017-24. PubMed ID: 24975670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.
    Kellermann SA; Green LL
    Curr Opin Biotechnol; 2002 Dec; 13(6):593-7. PubMed ID: 12482519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of DOTA-conjugated antibody fragments for radioimmunoimaging.
    Smith-Jones PM; Solit DB
    Methods Enzymol; 2004; 386():262-75. PubMed ID: 15120256
    [No Abstract]   [Full Text] [Related]  

  • 38. Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments.
    Tsai SW; Li L; Williams LE; Anderson AL; Raubitschek AA; Shively JE
    Bioconjug Chem; 2001; 12(2):264-70. PubMed ID: 11312688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formatting antibody fragments to mediate specific therapeutic functions.
    Weir AN; Nesbitt A; Chapman AP; Popplewell AG; Antoniw P; Lawson AD
    Biochem Soc Trans; 2002 Aug; 30(4):512-6. PubMed ID: 12196125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Therapeutic antibodies and related products: choosing the right structure for success].
    Beck A; Wagner-Rousset E; Wurch T; Corvaia N
    Med Sci (Paris); 2009 Dec; 25(12):1024-32. PubMed ID: 20035674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.